Publikasi Scopus 2010 s/d 2022

Authors_(Last_Name)

Thriemer K., Degaga T.S., Christian M., Alam M.S., Ley B., Hossain M.S., Kibria M.G., Tego T.T., Abate D.T., Weston S., Karahalios A., Rajasekhar M., Simpson J.A., Rumaseb A., Mnjala H., Lee G., Anose R.T., Kidane F.G., Woyessa A., Baird K., Sutanto I., Hailu A., Price R.N.

Author S Id

22982020800;57210995292;57698377200;25647489800;55004117400;57212814553;57211039037;57217112254;57217112429;57190372493;57226233017;57215545833;55568943500;57193706146;57696532400;57696532500;57697464400;57696844400;6508263278;54584819100;6603791639;7003570205;55544802200;

Title

Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)

Year

2022

Source Title

Trials

Volume

Issue

Art No

416

Page Start

Page End

Page Count

Cited By

Link

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130263942&doi=10.1186%2fs13063-022-06364-z&partnerID=40&md5=d3bf3e73502582929be39d5882ece7b2

Affiliations

Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia; College of Medicine & Health Sciences, Arba Minch University, Arba Minch, Ethiopia; Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia; International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh; Arba Minch General Hospital, Arba Minch, Ethiopia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia; Ethiopian Public Health Institute, Addis Ababa, Ethiopia; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom; Department of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Authors With Affiliations

Thriemer, K., Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia; Degaga, T.S., College of Medicine & Health Sciences, Arba Minch University, Arba Minch, Ethiopia; Christian, M., Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia; Alam, M.S., International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh; Ley, B., Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia; Hossain, M.S., International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh; Kibria, M.G., International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh; Tego, T.T., Arba Minch General Hospital, Arba Minch, Ethiopia; Abate, D.T., College of Medicine & Health Sciences, Arba Minch University, Arba Minch, Ethiopia; Weston, S., Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia; Karahalios, A., Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia; Rajasekhar, M., Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia; Simpson, J.A., Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia; Rumaseb, A., Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia; Mnjala, H., Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia; Lee, G., Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia; Anose, R.T., College of Medicine & Health Sciences, Arba Minch University, Arba Minch, Ethiopia; Kidane, F.G., College of Medicine & Health Sciences, Arba Minch University, Arba Minch, Ethiopia; Woyessa, A., Ethiopian Public Health Institute, Addis Ababa, Ethiopia; Baird, K., Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia, Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom; Sutanto, I., Department of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Hailu, A., College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; Price, R.N., Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia, Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Abstract

Background: Plasmodium vivax forms dormant liver stages that can reactivate weeks or months following an acute infection. Recurrent infections are often associated with a febrile illness and can cause a cumulative risk of severe anaemia, direct and indirect mortality, and onward transmission of the parasite. There is an increased risk of P. vivax parasitaemia following falciparum malaria suggesting a rationale for universal use of radically curative treatment in patients with P. falciparum malaria even in the absence of detectable P. vivax parasitaemia in areas that are co-endemic for both species. Methods: This is a multicentre, health care facility-based, randomized, controlled, open-label trial in Bangladesh, Indonesia and Ethiopia. Patients with uncomplicated falciparum malaria, G6PD activity of ≥70% of the adjusted male median (AMM) and haemoglobin levels ≥8g/dl are recruited into the study and randomized to either receive standard schizonticidal treatment plus 7-day high dose primaquine (total dose 7mg/kg) or standard care in a 1:1 ratio. Patients are followed up weekly until day 63. The primary endpoint is the incidence risk of any P. vivax parasitemia on day 63. Secondary endpoints include incidence risk on day 63 of symptomatic P. vivax malaria and the risk of any P. falciparum parasitaemia. Secondary safety outcomes include the proportion of adverse events and serious adverse events, the incidence risk of severe anaemia (Hb<5g/dl and <7g/dl) and/or the risk for blood transfusion, the incidence risk of ≥ 25% fall in haemoglobin with and without haemoglobinuria, and the incidence risk of ≥ 25% fall in haemoglobin to under 7g/dl with and without haemoglobinuria. Discussion: This study evaluates the potential benefit of a universal radical cure for both P. vivax and P. falciparum in different endemic locations. If found safe and effective universal radical cure could represent a cost-effective approach to clear otherwise unrecognised P. vivax infections and hence accelerate P. vivax elimination. Trial registration: NCT03916003. Registered on 12 April 2019. © 2022, The Author(s).

Author Keywords

Co-endemic; Falciparum malaria; Radical cure; Randomized controlled trial; Universal radical cure; Vivax elimination; Vivax malaria

Index Keywords

artemether; artemether plus benflumetol; artesunate; dihydroartemisinin plus piperaquine; DNA; glucose 6 phosphate dehydrogenase; hemoglobin; primaquine; antimalarial agent; primaquine; adolescent; adult; anemia; Article; Bangladesh; blood smear; blood transfusion; clinical article; controlled study; disease severity; DNA determination; DNA extraction; drug blood level; drug efficacy; drug megadose; drug safety; drug tolerability; enzyme activity; Ethiopia; female; genotyping; hemoglobin blood level; hemoglobinuria; high throughput sequencing; human; incidence; Indonesia; infection prevention; infection risk; infection sensitivity; intention to treat analysis; malaria falciparum; male; medication compliance; multicenter study; parasite transmission; patient compliance; physical examination

Funding Details

Bill and Melinda Gates Foundation; Australian Government; National Health and Medical Research Council; Australian Academy of Science; Department of Industry, Innovation and Science, Australian Government

Funding Text 1

Funding for this project is provided by the Australian Academy of Science, on behalf of the Department of Industry, Innovation and Science. The Regional Collaborations Programme is supported by the Australian Government under the National Innovation and Science Agenda. This work is also supported, in part, by the Bill & Melinda Gates Foundation INV-010504 and the Australian National Health and Med

Funding Text 2

Funding Text 3

Publisher

BioMed Central Ltd

Issn

17456215

Isbn

Pubmed Id

35585641

Document Type

Article

Sjr Best Quartile

Sjr

865

Sjr Rank

5100